Trials / Unknown
UnknownNCT06331650
A Single-arm Pilot Study of First-line Treatment With Carbognilumab Combined With Chemotherapy in Patients With STK11-mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Guangzhou Institute of Respiratory Disease · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and tolerability of carbognilumab combined with chemotherapy as the first-line treatment for patients with STK11 mutated advanced or postoperative recurrent non-small cell lung cancer (NSCLC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | cadonilimab | Cardunnilizumab: the recommended dose is 10mg/kg every 3 weeks on the first day of each cycle; Discontinuation of the drug may be considered if intolerable adverse reactions occur. |
Timeline
- Start date
- 2023-08-09
- Primary completion
- 2025-08-01
- Completion
- 2025-10-01
- First posted
- 2024-03-26
- Last updated
- 2024-03-26
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06331650. Inclusion in this directory is not an endorsement.